MTOR and prolactin-producing pituitary gland adenoma: Other therapeutic options have been proposed for DA resistant prolactinomas, such as metformin, selective estrogen modulators, somatostatin analogues, tyrosine kinase inhibitors, inhibitors of mammalian target of rapamycin (mTOR), immune checkpoint inhibitors and peptide radio-receptor therapy [3, 19].